Bone Biologics Corp

For the period ended Mar 31, 2026. Filed May 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

Consolidated Statement of Stockholders’ Equity

For the Three Months ended March 31, 2026

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2025	1,795,260	$1,795	$93,506,122	$(88,130,369)	$5,377,548
Fair value of vested stock options	-	-	23,505	-	23,505
Options issued to settle accrued bonus	-	-	34,854	-	34,854
Net Loss	-	-	-	(765,988)	(765,988)
Balance at March 31, 2026	1,795,260	$1,795	$93,564,481	$(88,896,357)	$4,669,919

Consolidated Statement of Stockholders’ Equity

For the Three Months ended March 31, 2025

(unaudited)(1)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2024(1)	492,417	492	88,504,543	(85,021,378)	3,483,657
Fair value of vested stock options(1)	-	-	50,605	-	50,605
Options issued to settle accrued bonus(1)	-	-	46,183	-	46,183
Issuance of common shares from ATM, net of costs of $13,029 (1)	52,843	53	347,496	-	347,549
Net Loss(1)	-	-	-	(1,017,092)	(1,017,092)
Balance at March 31, 2025(1)	545,260	$545	$88,948,827	$(86,038,470)	$2,910,902

(1)	Adjusted to reflect the reverse stock split as described in Note 1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.